1. Home
  2. TLSI vs ALCY Comparison

TLSI vs ALCY Comparison

Compare TLSI & ALCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • ALCY
  • Stock Information
  • Founded
  • TLSI 2010
  • ALCY 2021
  • Country
  • TLSI United States
  • ALCY United States
  • Employees
  • TLSI N/A
  • ALCY N/A
  • Industry
  • TLSI Medical Specialities
  • ALCY Blank Checks
  • Sector
  • TLSI Health Care
  • ALCY Finance
  • Exchange
  • TLSI Nasdaq
  • ALCY Nasdaq
  • Market Cap
  • TLSI 166.8M
  • ALCY 160.9M
  • IPO Year
  • TLSI N/A
  • ALCY 2023
  • Fundamental
  • Price
  • TLSI $4.67
  • ALCY $10.85
  • Analyst Decision
  • TLSI Strong Buy
  • ALCY
  • Analyst Count
  • TLSI 3
  • ALCY 0
  • Target Price
  • TLSI $12.67
  • ALCY N/A
  • AVG Volume (30 Days)
  • TLSI 77.7K
  • ALCY 55.2K
  • Earning Date
  • TLSI 11-12-2024
  • ALCY 01-01-0001
  • Dividend Yield
  • TLSI N/A
  • ALCY N/A
  • EPS Growth
  • TLSI N/A
  • ALCY N/A
  • EPS
  • TLSI N/A
  • ALCY 0.36
  • Revenue
  • TLSI $24,736,000.00
  • ALCY N/A
  • Revenue This Year
  • TLSI $61.24
  • ALCY N/A
  • Revenue Next Year
  • TLSI $47.32
  • ALCY N/A
  • P/E Ratio
  • TLSI N/A
  • ALCY $29.89
  • Revenue Growth
  • TLSI 67.75
  • ALCY N/A
  • 52 Week Low
  • TLSI $3.32
  • ALCY $10.31
  • 52 Week High
  • TLSI $10.42
  • ALCY $11.85
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 36.08
  • ALCY 56.61
  • Support Level
  • TLSI $4.43
  • ALCY $10.82
  • Resistance Level
  • TLSI $5.32
  • ALCY $10.86
  • Average True Range (ATR)
  • TLSI 0.36
  • ALCY 0.02
  • MACD
  • TLSI -0.04
  • ALCY -0.00
  • Stochastic Oscillator
  • TLSI 18.49
  • ALCY 50.00

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About ALCY Alchemy Investments Acquisition Corp 1

Alchemy Investments Acquisition Corp 1 is a blank check company.

Share on Social Networks: